CAS 67337-74-0: 2,4-Imidazolidinedione, 5-(hydroxymethyl)-

5-(Hydroxymethyl)imidazolidine-2,4-dione (HMI) is a synthetic compound that has been shown to be effective for the treatment of tuberculosis. HMI is an analog of d-serine and is immobilized on activated carbon to produce filtration media. It was found to be more efficient than other immobilization methods in terms of yield, operational time, and filtration capacity. The affinity and chiral properties of HMI make it a good candidate for use as a drug delivery system.